Drug Profile
Infliximab biosimilar - Bionovis/The Instituto Vital Brazil
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Bionovis; The Instituto Vital Brazil
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 05 Jun 2015 Launched for Ankylosing spondylitis in Brazil (IV) before June 2015
- 05 Jun 2015 Launched for Crohn's disease in Brazil (IV) before June 2015
- 05 Jun 2015 Launched for Plaque psoriasis in Brazil (IV) before June 2015